Megan Dowler
Walter Reed Army Institute of Research(US)
Publications by Year
Research Areas
Malaria Research and Control, Mosquito-borne diseases and control, vaccines and immunoinformatics approaches, Parasites and Host Interactions, HIV Research and Treatment
Most-Cited Works
- → Protection of Humans against Malaria by Immunization with Radiation‐AttenuatedPlasmodium falciparumSporozoites(2002)687 cited
- → Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection(2009)536 cited
- → Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalaria(2001)270 cited
- → Long‐Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine(1998)235 cited
- → Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A(2009)208 cited
- → Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design(2009)160 cited
- → First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers(2013)128 cited
- → Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research(2008)128 cited
- → A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults(2007)106 cited
- → Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection(2009)88 cited